Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Fineline Cube Jan 12, 2026
Company Deals

Mirxes Partners with Thailand’s N Health to Launch miRNA Cancer Screening

Fineline Cube Jan 12, 2026
Company Deals

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Fineline Cube Jan 12, 2026
Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Fineline Cube Jan 12, 2026
Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026
Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Fineline Cube Jan 12, 2026
Company Deals

NucMito and Amoytop Biotech Seal Deal for Development and Commercialization of NASH Drug Candidate in Greater China

Fineline Cube Oct 25, 2024

NucMito, a pioneering nuclear receptor drug developer headquartered in Xiamen, has entered into a licensing...

Company Deals

HELP Therapeutics Receives FDA Clearance for Phase I Clinical Trial of HiCM-188 Cell Therapy

Fineline Cube Oct 25, 2024

HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company headquartered in Nanjing, has announced that...

Company Deals

Merck Acquires Modifi Biosciences to Target DNA Repair Defects in Cancer Therapies

Fineline Cube Oct 24, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has bolstered...

Company Drug

Eli Lilly’s Alzheimer’s Drug Kisunla Secures Marketing Approval in Great Britain

Fineline Cube Oct 24, 2024

Eli Lilly & Co. (NYSE: LLY) has announced that it has received marketing approval in...

Company Medical Device

Sino Medical Sciences Technology Secures Marketing Approval for Coronary Balloon Dilation Catheter in Morocco

Fineline Cube Oct 24, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108) a China-based medical device company, has announced that...

Company Drug

Gan & Lee Pharmaceuticals Initiates Phase I Clinical Trial for Biosimilar Secukinumab

Fineline Cube Oct 24, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the commencement of...

Company Drug

Lundbeck’s Vyepti Migraine Treatment Available at Sun Yat-sen Memorial Hospital Through Greater Bay Area Policy

Fineline Cube Oct 24, 2024

Vyepti (eptinezumab), a migraine treatment developed by Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF),...

Company Drug

Lee’s Pharmaceutical’s Subsidiary Reports Positive Results from Phase III Myopia Treatment Study

Fineline Cube Oct 24, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology...

Policy / Regulatory

NMPA’s Center for Drug Evaluation Issues New Guidelines for Domestic Transfer of Overseas-Produced Vaccines

Fineline Cube Oct 24, 2024

The Center for Drug Evaluation under the National Medical Products Administration (NMPA) has issued the...

Company Deals

Eccogene Inc. Secures $60 Million Milestone Payment from AstraZeneca for ECC5004/AZD5004

Fineline Cube Oct 23, 2024

Sino-US firm Eccogene Inc. announced on October 23rd that it is set to receive a...

Company

Sunshine Guojian Pharma Reports Q3 Revenue Growth and Advances in Clinical Trials

Fineline Cube Oct 23, 2024

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530),...

Company Drug

LINDIS Biotech’s Catumaxomab Receives Positive Opinion from EMA’s COMP for Malignant Ascites Treatment

Fineline Cube Oct 23, 2024

LINDIS Biotech GmbH, a German biotechnology company, has announced that the Committee for Orphan Medicinal...

Policy / Regulatory

China’s NMPA Launches Pilot Program for Phased Manufacturing of Biological Products

Fineline Cube Oct 23, 2024

The National Medical Products Administration (NMPA) has officially released the “Pilot Work Plan for Phased...

Company Deals

Beijing Biostar Technologies Goes Public in Hong Kong to Fund Cancer Drug Development

Fineline Cube Oct 23, 2024

Beijing Biostar Technologies Ltd (HKG: 2563), a leading synthetic biology-driven anti-tumor drug specialist based in...

Company Medical Device

China Grand Pharmaceutical Receives NMPA Approval for Innovative Adjustable Thrombectomy Stent

Fineline Cube Oct 23, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has announced that it has...

Company Deals Drug

Grifols Partners with BARDA to Develop Treatment for Sulfur Mustard Ocular Injury

Fineline Cube Oct 23, 2024

Grifols (BME: GRF; NASDAQ: GRFS), a Spanish biopharmaceutical company, has announced a partnership with the...

Policy / Regulatory

Hunan Province Launches Pilot Program for Retail Sales of VBP Drugs with Strict Guidelines

Fineline Cube Oct 23, 2024

The Hunan Healthcare Security Administration has released the “Pilot Implementation Plan for Volume-based Procurement (VBP)...

Company Drug

Walvax Biotechnology’s Weuphoria Vaccine Approved in Oman for Pediatric Pneumococcal Infections

Fineline Cube Oct 23, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142), a Chinese biopharmaceutical company, has announced that it has...

Company Medical Device

German Endoscope Maker KARL STORZ Secures Marketing Approval for Disposable Ureteroscope in China

Fineline Cube Oct 23, 2024

KARL STORZ SE & Co. KG, a leading German endoscope manufacturer, has announced that it...

Company Drug

LENZ Therapeutics’ Presbyopia Therapy LNZ100 Accepted for FDA Review

Fineline Cube Oct 23, 2024

LENZ Therapeutics, Inc. (NASDAQ: LENZ), a US-based biopharmaceutical company, has announced that the US Food...

Posts pagination

1 … 221 222 223 … 607

Recent updates

  • Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC
  • Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1
  • Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer
  • Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease
  • Lynk Pharmaceuticals Reports Positive Phase III Data for Zemprocitinib in Rheumatoid Arthritis – Best‑in‑Class JAK1 Inhibitor Shows 79 % ACR20 Response
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Company Drug

Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.